ADARp150 counteracts whole genome duplication.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
27 Aug 2024
Historique:
accepted: 07 08 2024
revised: 10 07 2024
received: 08 03 2024
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 27 8 2024
Statut: aheadofprint

Résumé

Impaired control of the G1/S checkpoint allows initiation of DNA replication under non-permissive conditions. Unscheduled S-phase entry is associated with DNA replication stress, demanding for other checkpoints or cellular pathways to maintain proliferation. Here, we uncovered a requirement for ADARp150 to sustain proliferation of G1/S-checkpoint-defective cells under growth-restricting conditions. Besides its well-established mRNA editing function in inversely oriented short interspersed nuclear elements (SINEs), we found ADARp150 to exert a critical function in mitosis. ADARp150 depletion resulted in tetraploidization, impeding cell proliferation in mitogen-deprived conditions. Mechanistically we show that ADAR1 depletion induced aberrant expression of Cyclin B3, which was causative for mitotic failure and whole-genome duplication. Finally, we find that also in vivo ADAR1-depletion-provoked tetraploidization hampers tumor outgrowth.

Identifiants

pubmed: 39189458
pii: 7742386
doi: 10.1093/nar/gkae700
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : KWF Kankerbestrijding
ID : 11074
Organisme : Netherlands Cancer Institute

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.

Auteurs

Frank van Gemert (F)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Alexandra Drakaki (A)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Isabel Morales Lozano (IM)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Daniël de Groot (D)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Maud Schoot Uiterkamp (MS)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Natalie Proost (N)

Mouse Clinic for Cancer and Aging Research, Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Cor Lieftink (C)

Division of Molecular Carcinogenesis, NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Marieke van de Ven (M)

Mouse Clinic for Cancer and Aging Research, Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Roderick L Beijersbergen (RL)

Division of Molecular Carcinogenesis, NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Heinz Jacobs (H)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Hein Te Riele (H)

Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Classifications MeSH